EUVIMEDEUVIMED entdecken
Crossref

METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1

Xianfu Wei, Jinyan Feng, Long Chen, Chao Zhang, Yongheng Liu, Yan Zhang, Yao Xu, Jin Zhang, Jinwu Wang, Houzhi Yang, Xiuxin Han, Guowen Wang

Cancer Letters · 2025-02 · 611 · 217194

DOI: 10.1016/j.canlet.2024.217194 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025-02. Verfasst von Xianfu Wei und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China; State Key Laboratory …. Hauptthemen laut MEDLINE: Osteosarcoma, Drug Resistance, Neoplasm, Phosphopyruvate Hydratase, Tumor Suppressor Proteins. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemoresistance remains the main obstacle limiting the treatment of osteosarcoma, seriously affecting the prognosis of adolescent patients with osteosarcoma. Recently, long non-coding RNAs (lncRNAs) were reported to be involved in chemoresistance, while the mechanisms of lncRNAs underlying osteosarcoma resistance to chemotherapy remain elusive. Here, LINC00520 was identified as a novel cisplatin resistance-related lncRNA in osteosarcoma, and its high expression was associated with poor prognosis of osteosarcoma patients. Functionally, LINC00520 could potentiate osteosarcoma resistance to cisplatin in vitro and in vivo. Mechanistically, LINC00520 bound to ENO1 and upregulated ENO1 protein expression by blocking FBXW7-mediated ENO1 ubiquitination and proteasomal degradation, thereby promoting glycolysis and ultimately inducing cisplatin resistance in osteosarcoma. Furthermore, METTL3 could stabilize and upregulate LINC00520 in an m6A-YTHDF2-dependent manner in osteosarcoma. This study proposes a novel lncRNA-driven mechanism for cisplatin resistance in osteosarcoma, and offers a promising therapeutic strategy for reversing chemoresistance in osteosarcoma by targeting the METTL3/LINC00520/ENO1/glycolysis axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaDrug Resistance, NeoplasmPhosphopyruvate HydrataseTumor Suppressor ProteinsRNA, Long NoncodingMethyltransferasesBone NeoplasmsDNA-Binding ProteinsHumansUbiquitinationCisplatinAnimalsGlycolysisCell Line, TumorMiceGene Expression Regulation, NeoplasticRNA MethylationRNA-Binding ProteinsMice, NudePrognosisAdenosine

Stichwörter der Autor:innen

ChemoresistanceENO1GlycolysisLINC00520OsteosarcomaUbiquitination

Substanzen

Phosphopyruvate HydrataseTumor Suppressor ProteinsCisplatinENO1 protein, humanRNA, Long NoncodingMethyltransferasesMETTL3 protein, humanRNA-Binding ProteinsN-methyladenosineDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China; State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Nati…

Zitieren

APA

Wei, X., Feng, J., Chen, L., Zhang, C., Liu, Y., Zhang, Y., Xu, Y., Zhang, J., Wang, J., Yang, H., Han, X., & Wang, G. (2025). METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1. Cancer Letters, 611, 217194. https://doi.org/10.1016/j.canlet.2024.217194

Vancouver

Wei X, Feng J, Chen L, Zhang C, Liu Y, Zhang Y, et al. METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1. Cancer Letters. 2025;611:217194. doi:10.1016/j.canlet.2024.217194

BibTeX
@article{Wei2025,
  author = {Wei, Xianfu and Feng, Jinyan and Chen, Long and Zhang, Chao and Liu, Yongheng and Zhang, Yan and Xu, Yao and Zhang, Jin and Wang, Jinwu and Yang, Houzhi and Han, Xiuxin and Wang, Guowen},
  title = {METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1},
  journal = {Cancer Letters},
  year = {2025},
  volume = {611},
  pages = {217194},
  doi = {10.1016/j.canlet.2024.217194}
}
Kostenlos starten →